A novel gene therapy developed by bluebird bio Inc of Cambridge, Massachusetts has been administered to a patient with beta-thalassemia, a rare blood disorder. The treatment involves an autologous haematopoietic stem cell transplantation. ---Subscribe to MedNous to access this article--- Company News Regenerative Medicine Clinical Research
